We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00159614
First Posted: September 12, 2005
Last Update Posted: January 29, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by:
NovaCardia, Inc.
  Purpose
The purpose of this study is to characterize the safety and tolerability of KW-3902IV and measure its effect on renal function.

Condition Intervention Phase
Heart Failure, Congestive Renal Insufficiency Drug: KW-3902IV Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With Congestive Heart Failure (CHF) and Renal Impairment

Resource links provided by NLM:


Further study details as provided by NovaCardia, Inc.:

Primary Outcome Measures:
  • Comparison of KW-3902IV alone or with loop diuretic on renal function.

Estimated Enrollment: 30
Study Start Date: September 2005
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Stable congestive heart failure
  • Impaired renal function
  • Taking oral loop diuretic

Exclusion Criteria:

  • Acutely decompensated (unstable) and end stage heart failure
  • Diuretics other than loop diuretics
  • Pregnant or nursing
  • Inability to follow instructions
  • Participation in another clinical trial within past 30 days
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00159614


Locations
United States, California
San Diego, California, United States
United States, Maryland
Baltimore, Maryland, United States
United States, Massachusetts
Ayer, Massachusetts, United States
Boston, Massachusetts, United States
United States, Michigan
Kalamazoo, Michigan, United States
United States, Tennessee
Tullahoma, Tennessee, United States
Sponsors and Collaborators
NovaCardia, Inc.
Merck Sharp & Dohme Corp.
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00159614     History of Changes
Other Study ID Numbers: CKI-203
First Submitted: September 7, 2005
First Posted: September 12, 2005
Last Update Posted: January 29, 2008
Last Verified: January 2008

Keywords provided by NovaCardia, Inc.:
renal insufficiency
diuretic
heart failure, congestive

Additional relevant MeSH terms:
Heart Failure
Renal Insufficiency
Heart Diseases
Cardiovascular Diseases
Kidney Diseases
Urologic Diseases
Furosemide
Rolofylline
Diuretics
Natriuretic Agents
Physiological Effects of Drugs
Sodium Potassium Chloride Symporter Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action